Jashodeep Datta1,2, Raja R Narayan1,3, Debra A Goldman4, Walid K Chatila5,6,7, Mithat Gonen4, James Strong1, Vinod P Balachandran1, Jeffrey A Drebin1, T Peter Kingham1, William R Jarnagin1, Nikolaus Schultz4,5,6, Nancy E Kemeny8, Michael I D'Angelica1. 1. Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Division of Surgical Oncology, Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida. 3. Department of Surgery, Stanford University School of Medicine, Stanford, California. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, New York. 8. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
OBJECTIVE: To examine genomic correlates of conversion to resection (CTR and overall survival (OS) in patients with initially unresectable colorectal liver metastasis (IU-CRLM) treated with combination systemic and hepatic artery infusion (HAI) chemotherapy. BACKGROUND: In patients presenting with IU-CRLM, combination systemic and HAI chemotherapy enables CTR with associated long-term OS in a subset of patients. Genomic correlates of CTR and OS in IU-CRLM have not been previously explored. METHODS: Specimens from IU-CRLM patients receiving systemic/HAI chemotherapy (2003-2017) were submitted for next-generation sequencing. Fisher Exact test assessed associations with CTR, and Kaplan-Meier/Cox methods assessed associations with OS from HAI initiation. RESULTS: Of 128 IU-CRLM patients, 51 (40%) underwent CTR at median 6 months (range: 3-35) from HAI initiation. CTR and persistently unresectable cohorts differed significantly in preoperative systemic chemotherapy exposure, node-positive primary status, and size of largest liver metastasis. Median and 5-year OS was 66 months and 51%. CTR was associated with prolonged survival (time-dependent HR 0.23,95% CI: 0.12-0.46, P < 0.001). The most frequently altered genes were APC (81%), TP53 (77%), and KRAS (37%). Oncogenic mutations in SOX9 and BRAF were associated with CTR. BRAF mutations, any RAS pathway alterations, and co-altered RAS/RAF-TP53 mutations wereassociated with worse survival. Classification and regression tree analysis defined prognostically relevant clusters of genomic risk to reveal co-altered RAS/RAF-TP53 as the highest risk subgroup. Co-altered RAS/RAF-TP53 remained independently associated with worse survival (HR 2.52, 95% CI: 1.37-4.64, P = 0.003) after controlling for CTR, number of liver metastases, and preoperative extrahepatic disease. CONCLUSIONS: Distinct genomic profiles are associated with CTR and survival in patients with IU-CRLM treated with HAI/systemic chemotherapy. Presence of SOX9, BRAF , and co-altered RAS/RAF- TP53 mutations are promising biomarkers that, when validated in larger datasets, may impact treatment of IU-CRLM patients.
OBJECTIVE: To examine genomic correlates of conversion to resection (CTR and overall survival (OS) in patients with initially unresectable colorectal liver metastasis (IU-CRLM) treated with combination systemic and hepatic artery infusion (HAI) chemotherapy. BACKGROUND: In patients presenting with IU-CRLM, combination systemic and HAI chemotherapy enables CTR with associated long-term OS in a subset of patients. Genomic correlates of CTR and OS in IU-CRLM have not been previously explored. METHODS: Specimens from IU-CRLM patients receiving systemic/HAI chemotherapy (2003-2017) were submitted for next-generation sequencing. Fisher Exact test assessed associations with CTR, and Kaplan-Meier/Cox methods assessed associations with OS from HAI initiation. RESULTS: Of 128 IU-CRLM patients, 51 (40%) underwent CTR at median 6 months (range: 3-35) from HAI initiation. CTR and persistently unresectable cohorts differed significantly in preoperative systemic chemotherapy exposure, node-positive primary status, and size of largest liver metastasis. Median and 5-year OS was 66 months and 51%. CTR was associated with prolonged survival (time-dependent HR 0.23,95% CI: 0.12-0.46, P < 0.001). The most frequently altered genes were APC (81%), TP53 (77%), and KRAS (37%). Oncogenic mutations in SOX9 and BRAF were associated with CTR. BRAF mutations, any RAS pathway alterations, and co-altered RAS/RAF-TP53 mutations wereassociated with worse survival. Classification and regression tree analysis defined prognostically relevant clusters of genomic risk to reveal co-altered RAS/RAF-TP53 as the highest risk subgroup. Co-altered RAS/RAF-TP53 remained independently associated with worse survival (HR 2.52, 95% CI: 1.37-4.64, P = 0.003) after controlling for CTR, number of liver metastases, and preoperative extrahepatic disease. CONCLUSIONS: Distinct genomic profiles are associated with CTR and survival in patients with IU-CRLM treated with HAI/systemic chemotherapy. Presence of SOX9, BRAF , and co-altered RAS/RAF- TP53 mutations are promising biomarkers that, when validated in larger datasets, may impact treatment of IU-CRLM patients.
Authors: Vincent W T Lam; Calista Spiro; Jerome M Laurence; Emma Johnston; Michael J Hollands; Henry C C Pleass; Arthur J Richardson Journal: Ann Surg Oncol Date: 2011-09-16 Impact factor: 5.344
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger Journal: J Mol Diagn Date: 2015-03-20 Impact factor: 5.568
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: Yun Shin Chun; Guillaume Passot; Suguru Yamashita; Maliha Nusrat; Panagiotis Katsonis; Jonathan M Loree; Claudius Conrad; Ching-Wei D Tzeng; Lianchun Xiao; Thomas A Aloia; Cathy Eng; Scott E Kopetz; Olivier Lichtarge; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2019-05 Impact factor: 12.969
Authors: Breanna M Javier; Rona Yaeger; Lu Wang; Francisco Sanchez-Vega; Ahmet Zehir; Sumit Middha; Justyna Sadowska; Efsevia Vakiani; Jinru Shia; David Klimstra; Marc Ladanyi; Christine A Iacobuzio-Donahue; Jaclyn F Hechtman Journal: Oncotarget Date: 2016-08-09
Authors: Jennifer P Morton; Paul Timpson; Saadia A Karim; Rachel A Ridgway; Dimitris Athineos; Brendan Doyle; Nigel B Jamieson; Karin A Oien; Andrew M Lowy; Valerie G Brunton; Margaret C Frame; T R Jeffry Evans; Owen J Sansom Journal: Proc Natl Acad Sci U S A Date: 2009-12-14 Impact factor: 11.205
Authors: Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2022-07-27 Impact factor: 4.339
Authors: Austin R Dosch; Walid K Chatila; Yuguang Ban; Anna Bianchi; Nilesh U Deshpande; Iago De Castro Silva; Nipun B Merchant; Jashodeep Datta Journal: Oncotarget Date: 2021-09-28
Authors: Helena Isoniemi; Pia Osterlund; Aki Uutela; Emerik Osterlund; Päivi Halonen; Raija Kallio; Annika Ålgars; Tapio Salminen; Annamarja Lamminmäki; Leena-Maija Soveri; Raija Ristamäki; Kaisa Lehtomäki; Hanna Stedt; Eetu Heervä; Timo Muhonen; Juha Kononen; Arno Nordin; Ali Ovissi; Soili Kytölä; Mauri Keinänen; Jari Sundström; Lasse Nieminen; Markus J Mäkinen; Teijo Kuopio; Ari Ristimäki Journal: Br J Cancer Date: 2022-05-24 Impact factor: 9.075